Increasing interest in our Pricing Model and Algorithm for "expensive" drugs

In 2016 we introduced a change in the paradigm in reimbursement decisions on innovative drugs. We published a novel pricing model from a broader perspective that bridges concepts from health economics and business economic valuation. This algorithm may justify a drug price, when drug is not cost-effective (> € 80,000/QALY).  We gave numerous workshops on this new pricing algorithm: Some examples:  1) VVD – Dutch Liberal Party - The Hague, June 6, 2018  2) Ministry of Health (VWS) - The Hague, March 22, 2018 3) Association Innovative Medicines: Kennisatelier Prijsmodellen – The Hague, October 25, 2017  4) EURORDIS: Paris, June 16, 2017 5) ITU Economics, Istanbul, September 20, 201 6) Biotechnology companies: Internal workshops and pricing negotiation support.